title: A possible antienuretic effect of reboxetine in children and adolescents with attention deficit/hyperactivity disorder: case series.
abstract: Reboxetine is a selective norepinephrine reuptake inhibitor.
  
  
  OBJECTIVE
  To evaluate the antienuretic effect of reboxetine in children with attention deficit and mood disorders.
  
  
  METHODS
  Six children aged 12-15 years with primary nocturnal enuresis and with attention deficit/hyperactivity disorder with or without other comorbid disorders were treated with reboxetine (4-8 mg/day). Monitoring of enuretic frequency was recorded at baseline and once a week for 6 weeks.
  
  
  RESULTS
  A statistically significant decrease in bedwetting was noted along the assessment points (p < 0.001), with the maximal change noted in the first week of treatment (p = 0.004). Reboxetine was well tolerated with minimal and transient side effects.
  
  
  CONCLUSIONS
  reboxetine may possess an antienuretic effect in some children with the attention deficit/hyperactivity disorder.
authors.affiliation: Tel Aviv-Brull Community Mental Health Center, 1 Geiger Street, Basement Floor, Ramat-Aviv, Tel Aviv 69341, Israel.
authors.forename: Paz
authors.initials: P
authors.lastname: Toren
authors.forename: Sharon
authors.initials: S
authors.lastname: Ratner
authors.forename: Nathaniel
authors.initials: N
authors.lastname: Laor
authors.forename: Dana
authors.initials: D
authors.lastname: Lerer-Amisar
authors.forename: Abraham
authors.initials: A
authors.lastname: Weizman
mesh_terms: D000293:Adolescent; D000704:Analysis of Variance; D001289:Attention Deficit Disorder with Hyperactivity / Q000150:complications / Q000188:drug therapy*; D002648:Child; D004775:Enuresis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D009025:Morpholines / Q000627:therapeutic use*; D000077593:Reboxetine; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D009025:Morpholines; D000077593:Reboxetine